Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lotilaner in Ocular Rosacea
NCT07443202Phase 2Enrolling by invitation
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lotilaner in ocular rosacea, sponsored by Tarsus Pharmaceuticals, Inc.. Started Dec 2025; status: enrolling by invitation.
02
Drugs
lotilaner
03
Conditions
ocular rosacea
Beyond the preview
Go deeper on NCT07443202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07443202.